Alterity Therapeutics (ATHE) Debt to Equity (2015)

Alterity Therapeutics (ATHE) recorded quarterly Debt to Equity of $0.0 in Q2 2015.

Alterity Therapeutics (ATHE) Debt to Equity (2015) Analysis & Trends

Alterity Therapeutics' Debt to Equity history runs 1 years deep, the most recent figure standing at $0.0 for Q2 2015.

In Q2 2015, Debt to Equity changed N/A year-over-year to $0.0; the TTM figure through Jun 2015 stood at $0.0 (changed N/A YoY), while the FY2015 annual figure was $0.0, changed N/A from the prior year.
Debt to Equity was $0.0 for Q2 2015 at Alterity Therapeutics.
In the past five years, Debt to Equity ranged from a high of $0.0 in Q2 2015 to a low of $0.0 in Q2 2015.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	0.32
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	-
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Regeneron Pharmaceuticals	63.59 Bn	54.83 Bn	3.31 Bn	0.06

Historic Data

Download Data

Date	Value
Jun 30, 2015	0.00